Bladder Cancer: Eight-Market Drug Forecast and Market Analysis
Summary
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for bladder cancer.
These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.
MF, also called osteobladder cancer is a rare blood disorder that causes bone marrow (BM) fibrosis. Despite being a rare blood cancer, MF is a blockbuster market and is expected to grow from sales of $2.39 billion in 2021 to $2.89 billion in 2031 at a compound annual growth rate (CAGR) of 1.9%.
Key Highlights
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook